MeDucation· @MeDucationai · X·· 1 天前评分70
正文 · 原文
@dplanchard puts the action item first: MET testing for every EGFR-mutant patient progressing on osimertinib. Pearl for fellows: SAFFRON selected by IHC overexpression or FISH amplification, so order both on the re-biopsy. #ESMO26 #LCSM
2 浏览 · 0 赞 · 0 转发 · 0 回复
A major new milestone post-osimertinib! Totally agree with Natasha: a new therapeutic standard, MET testing for all our #EGFRm pts with disease progression post-Osi, and access to Osi + Savolitinib (now the most difficult step for our patients upon our return post-#ESMO26)...在 X 查看被引用的帖子
来源：MeDucation · x.com